A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Phase of Trial: Phase III
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Savolitinib (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms SAVOIR
- Sponsors AstraZeneca
- 11 Aug 2017 Planned End Date changed from 19 Feb 2021 to 30 Jun 2021.
- 11 Aug 2017 Planned primary completion date changed from 19 Feb 2021 to 31 Mar 2020.
- 29 Jun 2017 This trial has been designed to support product registration in the US and Europe according to a Chi-Med media release.